Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0007379 | Neoplasm of the genitourinary tract HPO | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
The identification of patients with genitourinary tumors who suffer from the infection by the Serious Acute Respiratory Syndrome Corona-Virus 2 (SARS-CoV-2) virus can represent multiple benefits both for themselves and for health professionals and the health system itself. We would be able to know more precisely the clinical evolution of these type of patient, to know their prognosis and being capable to select the most appropriate treatment modality for future pandemics. SOGUG-COVID is an observational prospective-retrospective trial purely epidemiological, that aims to describe the population with genitourinary tumors (urothelial cancer, prostate cancer, testicular cancer and kidney cancer) infected by COrona VIrus Disease 19 (COVID-19) treated in Spanish hospitals, learn about the clinical presentation, therapeutic evolution and prognosis of said intercurrent infectious process, as well as its possible relationship with different clinical and therapeutic factors.
Description: Describe the population infected by COVID-19 with genitourinary tumors (urothelial cancer, prostate cancer, testicular cancer and kidney cancer) treated in Spanish hospitals, know the clinical presentation: Age, gender, cancer type. Categorical variables will be presented as counts and percentages.
Measure: Baseline characteristics Time: Through study completion, average 1 yearDescription: Percentage of patients with complications associated to COVID-19 infection (classified by type and severity)
Measure: Frequency of complications of COVID-19 intercurrent infection Time: Through study completion, average 1 yearDescription: To assess the possible relationship of the different oncological treatments administered to these patients with the clinical evolution of the COVID-19 infection. Complications will be classified by type and severity in groups of patients stratified by the oncological treatment received.
Measure: Frequency of complications of COVID-19 infection in patients stratified by oncological treatment Time: Through study completion, average 1 yearDescription: To specifically assess the impact of COVID-19 infection on the toxicity of immunotherapy treatment (mainly pneumonitis) and the impact of immunotherapy on the evolution of the infectious picture in patients with tumors of genitourinary origin. three different scenarios: during treatment, after treatment and in patients who receive treatment after the infection has passed.
Measure: Frequency of adverse events related to immunotherapy targeted to cancer (classified by type and severity) Time: Through study completion, average 1 year. Measured at 3 scenarios (during treatment, after treatment and therapies indicated after infection has passed)Description: To evaluate in patients with Prostate Cancer (PCa) the impact of androgen deprivation therapy (ADT) and new antiandrogenic agents (NAH) with or without corticosteroids on the infection COVID-19 as mean of frequency in complications of COVID-19 infection classified by type and severity
Measure: Frequency of complications of COVID-19 infection in patients with prostate cancer stratified by anti-androgenic oncological treatment Time: Through study completion, average 1 yearDescription: To assess the mortality associated with COVID-19 infection in the population with genitourinary tumors. Percentage of patients alive / dead at discharge.
Measure: COVID-19 mortality rate in patients with genitourinary cancer Time: Through study completion, average 1 yearDescription: Evaluate the rate (percentage) of complications that have required hospital admission and / or ICU treatment. Complications will be classified by type and severity and represented as percentage of patients presenting them.
Measure: COVID-19 complication rate in patients with genitourinary cancer Time: Through study completion, average 1 yearDescription: Describe the frequency of asymptomatic or minimally symptomatic COVID-19 infections.
Measure: Asymptomatic rate Time: Through study completion, average 1 yearDescription: delays / modifications in cancer follow-up or treatment regimens. The average delay time and the number of modifications will be evaluated.
Measure: Frequency of delays/modifications on cancer treatment schedule Time: Through study completion, average 1 yearDescription: It is expected to obtain data on time to progression and overall survival of cancer patients, which can be compared with the reference values for each type of tumor pathology
Measure: Progression free survival in patients with genitourinary tumors that suffered COVID-19 Time: Through study completion, average 1 yearDescription: It is expected to obtain data on time to progression and overall survival of cancer patients, which can be compared with the reference values for each type of tumor pathology
Measure: Overall survival in patients with genitourinary tumors that suffered COVID-19 Time: Through study completion, average 1 yearAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports